Urgent Recall of Common Blood Pressure Medication Ramipril Issued Amid Dizziness Warning
Crescent Pharma Limited has initiated an urgent recall for a specific batch of Ramipril 5 mg Capsules, a widely prescribed medication for high blood pressure, following the discovery of a potential manufacturing error. The recall targets Batch Number GR164099, with authorities warning patients about the risk of dizziness and other side effects.
Manufacturing Error Leads to Incorrect Medication in Packaging
The Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed that the recall is due to a packaging mix-up. Cartons labelled as Ramipril 5 mg Capsules may incorrectly contain blister strips of Amlodipine 5 mg Tablets instead. This error occurred during the manufacturing process, raising concerns about patient safety and medication integrity.
Patients are strongly advised to check their Ramipril packaging immediately for the batch number GR164099. If affected, they should return the packs to their pharmacist without delay. The MHRA has issued clear instructions to ensure swift action to prevent further distribution or use of the compromised medication.
Low Risk but Medical Advice Recommended for Affected Patients
While the risk is considered low, as both Ramipril and Amlodipine are used to treat high blood pressure, patients who may have taken the incorrectly supplied Amlodipine are urged to seek medical advice if they experience any adverse effects. Common side effects to watch for include:
- Dizziness or lightheadedness
- Headaches
- Fatigue or weakness
- Swelling in the extremities
The MHRA reassures that the therapeutic overlap between the two drugs minimises severe health risks, but caution is paramount to avoid complications, especially in individuals with specific medical conditions or those on other medications.
Healthcare Professionals Instructed to Return Stock
In response to the recall, pharmacy and healthcare professionals have been directed by the MHRA to return all remaining stock of the affected batch to their suppliers. This measure aims to contain the issue and ensure that no further packs enter the supply chain. The agency is monitoring the situation closely to assess the extent of the error and implement corrective actions.
This incident highlights the critical importance of rigorous quality control in pharmaceutical manufacturing. Patients and healthcare providers are encouraged to stay vigilant and report any concerns to regulatory authorities to safeguard public health.
